Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Sept 2016

Yang Jiao, Li Shuting, Wang Biyuan, Wu Yinying, Chen Zheling, Lv Meng, Lin Yayun, Yang Jin

Abstract excerpt

Anti-epidermal growth factor receptor (EGFR) therapy has established efficacy in metastatic colorectal cancer, but a significant number of patients do not respond to such treatment. Recently, various biomarkers were reported to be useful in predicting resistance to anti-EGFR. All the potential biomarkers predicting resistance to anti-EGFR are reviewed herein from five aspects. First, upstream molecules, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MicroRNAs

Share to Neoplasm Metastasis

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins B-raf

Share to PTEN Phosphohydrolase

Source

Identifiers

PMID: 27422777
DOI: 10.1007/s13277-016-5140-9

Genes

EGFR
AREG
BRAF
EREG
HGF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.PMID 27422777Read ↗

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Semantic proximity Read ↗

EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.Semantic proximity Read ↗

Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.Semantic proximity Read ↗

Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerSemantic proximity Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

[Biomarkers of Anti-EGFR Antibodies in the Treatment of Metastatic Colorectal Cancer].Semantic proximity Read ↗

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovationSemantic proximity Read ↗

Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.